Anteo Diagnostics (ASX:ADO) has provided an update on one of its healthcare diagnostic partners, Ellume, that integrates AnteoBind into its products.
Anteo has partnered with Ellume since 2016, an Australian-based diagnostics company that develops, manufactures and commercialises connected products for health professionals and consumers.
Ellume focuses on detecting common illnesses affecting the global population where digital connectivity has the potential to value-add and improve patient care.
"It has developed a novel detection technology which integrates its unique quantum dot nanoparticles with novel optics, electronics, and software into an intuitive and high-performance digital platform," said Anteo in a statement.
Ellume has announced two recent global partnerships – one in December last year with GlaxoSmithKline (GSK) focused on improving respiratory care.
It announced a second partnership this month with NYSE-listed QIAGEN that is developing an advanced test for tuberculosis incorporating Ellume’s diagnostic capabilities.
Anteo Diagnostics said it has enjoyed a positive and collaborative R&D partnership with Ellume, adding it looks forward to helping the company establish more such partnerships.
According to Anteo's CEO Christopher Parker, “Ellume’s outstanding commercial success clearly endorses the performance-enhancing capabilities of AnteoBind and the unique possibilities it allows within the diagnostic development process.
"It is pleasing to see the transformation of our partnership from R&D to nearterm commercialization opportunities. Broadening the number of commercial partnerships is a key focus for Anteo’s team this calendar year and Ellume’s success gives further impetus to this objective.
“We are currently working on multiple partnerships having the potential for commercialisation opportunities with respect to AnteoBind. The recently announced distribution agreement with China-based Shanghai GeneoDX Biotechnology could significantly broaden the number of commercial partnerships. We look forward to updating shareholders on current opportunities as well as planned next steps with GeneoDX.”
Ellume’s founder and CEO Sean Parsons said: “Anteo has been a terrific development partner for Ellume and we look forward to building upon this relationship as we head into the commercialisation phase of the business. The Anteo team have a deep understanding of the industry and their technology, which makes them an excellent partner for developers and manufacturers of diagnostic products.”